Roberta Caputo
Overview
Explore the profile of Roberta Caputo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
644
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berton Giachetti P, Morganti S, Gandini S, Giudici F, Marra A, Nicolo E, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2461067.
PMID: 39982725
Importance: Endocrine therapy (ET) combined with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) agents is the standard first-line treatment for patients with hormone receptor-positive, ERBB2 (formerly HER2 or HER2/neu)-negative metastatic breast cancer....
2.
Arecco L, Blondeaux E, Bruzzone M, Arpino G, De Angelis C, De Laurentiis M, et al.
J Natl Cancer Inst
. 2025 Feb;
PMID: 39908473
Background: The monarchE and NATALEE trials employed different high-risk inclusion criteria. Main objective is to assess prognostic differences based on their inclusion criteria. Methods: Patients with hormone receptor-positive/HER2-negative early breast...
3.
Fabi A, Rossi A, Caputo R, Pisegna S, Scagnoli S, Pantano F, et al.
NPJ Precis Oncol
. 2025 Jan;
9(1):22.
PMID: 39843642
Tumor dissemination to the central nervous system (CNS) is almost a rule in the treatment journey of advanced HER2+ breast cancer (BC). Recent results demonstrated high intracranial efficacy with Trastuzumab...
4.
Buono G, Capozzi M, Caputo R, Lauro V, Cianniello D, Piezzo M, et al.
Cancer Treat Rev
. 2025 Jan;
133:102868.
PMID: 39798230
Within the expanding therapeutic landscape for breast cancer (BC), metastatic breast cancer (MBC) remains virtually incurable and tend to develop resistance to conventional treatments ultimately leading to metastatic progression and...
5.
Buonaiuto R, Caltavituro A, Tafuro M, Longobardi A, Pavone G, De Santis P, et al.
Breast
. 2024 Nov;
79:103833.
PMID: 39579620
Background: The combination of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) with endocrine therapy (ET) is the standard of care for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative...
6.
Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, et al.
NPJ Breast Cancer
. 2024 Aug;
10(1):68.
PMID: 39095493
No abstract available.
7.
Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, et al.
NPJ Breast Cancer
. 2024 Jul;
10(1):58.
PMID: 39019916
Abemaciclib demonstrated clinical benefit in women affected by HR+/HER2- advanced breast cancer (aBC). Drug-drug interactions (DDIs) can lead to reduced treatment efficacy or increased toxicity. This retro-prospective study aimed to...
8.
Blondeaux E, Xie W, Carmisciano L, Mura S, Sanna V, De Laurentiis M, et al.
EClinicalMedicine
. 2024 Apr;
70:102501.
PMID: 38685923
Background: Intermediate clinical endpoints (ICEs) are frequently used as primary endpoint in randomised trials (RCTs). We aim to assess whether changes in different ICEs can be used to predict changes...
9.
Caputo R, Buono G, Piezzo M, Martinelli C, Cianniello D, Rizzo A, et al.
Front Oncol
. 2024 Apr;
14:1362641.
PMID: 38595817
Objective: The objective of this multicenter, observational, retrospective analysis was to evaluate the safety and efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer (mTNBC) patients managed according to common...
10.
Miglietta F, Pontolillo L, De Angelis C, Caputo R, Marino M, Bria E, et al.
Breast
. 2024 Mar;
75():103713.
PMID: 38493590
Background: The last years have seen unprecedented improvement in breast cancer (BC) survival rates. However, this entirely apply to female BC patients, since gender minorities (male, transgender/gender-diverse) are neglected in...